SPOTLIGHT -
Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL
Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.
Read More
Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL
Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.
Dr. Jain on the Rationale to Evaluate Ibrutinib/Rituximab in MCL
Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.
Dr. Jain on Future Research Efforts Examining Venetoclax Resistance Patterns in MCL
Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.
Dr. Jain on the Activity of Venetoclax in MCL
Preetesh Jain, MD, PhD, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).
Dr. Jain on Next Steps for Venetoclax in Relapsed MCL
Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.
Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL
Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
